Forma Therapeutics Holdings, Inc. (FMTX) Stock Analysis
DELISTED 2022
What happened to Forma Therapeutics Holdings, Inc. (FMTX) stock?
Forma Therapeutics Holdings, Inc. (FMTX) no longer trades on public markets. It was delisted in October 2022. The figures below are historical and are not a current quote.
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Forma Therapeutics Holdings, Inc. (FMTX) trades at $20.01. Forma Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for rare hematologic diseases and cancers. Sector: Healthcare.
Last analyzed: May 6, 2026Analyst Coverage for FMTX: FMTX does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates FMTX against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
FMTX: 1/2 scored disciplines lean bearish. Dominant signal: Ray Dalio bullish.
How is this calculated? →Forma Therapeutics Holdings, Inc. (FMTX) Healthcare & Pipeline Overview
Forma Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company acquired by Novo Nordisk, focuses on developing novel therapeutics for rare hematologic diseases and cancers. Its pipeline includes treatments for sickle cell disease, prostate cancer, acute myeloid leukemia, and liver-related conditions, positioning it within the competitive biotechnology landscape.
What Is the Investment Thesis for FMTX?
Forma Therapeutics Holdings, Inc. presents an investment proposition centered on its innovative pipeline of therapeutics targeting rare hematologic diseases and cancers. Key value drivers include the clinical progress of FT-4202 in treating sickle cell disease and FT-7051 for metastatic castration-resistant prostate cancer. The development of Olutasidenib for acute myeloid leukemia and glioma, along with FT-8225 for liver-related conditions, further diversifies the company's portfolio. The acquisition by Novo Nordisk in October 2022 provides Forma with financial stability and resources to accelerate its clinical programs. However, the company faces risks associated with clinical trial outcomes, regulatory approvals, and competition from other biopharmaceutical companies. The success of Forma's pipeline will depend on positive clinical data and successful commercialization strategies. The company's beta of -0.95 suggests a lower volatility compared to the market, which may appeal to risk-averse investors.
Based on FMP financials and quantitative analysis
FMTX Key Highlights
FT-4202 is in Phase 1 trial for the treatment of sickle cell disease and other hemoglobinopathies.
- FT-7051 is being developed for the treatment of metastatic castration-resistant prostate cancer.
- Olutasidenib is in Phase II trial for the treatment of relapsed/refractory acute myeloid leukemia and Phase I trial to treat glioma.
- FT-8225 is a liver-targeted fatty-acid synthase inhibitor designed to block de novo lipogenesis in the liver.
- Forma Therapeutics Holdings, Inc. was acquired by Novo Nordisk A/S on October 14, 2022.
Who Are FMTX's Competitors?
FMTX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| BLUE bluebird bio, Inc. | $4.97 | +0.00% | $48.7M | 67 |
| CRSP CRISPR Therapeutics AG | $58.90 | -1.52% | $5.68B | 44 |
| BEAM Beam Therapeutics Inc. | $29.07 | +9.41% | $2.99B | — |
| VRTX Vertex Pharmaceuticals Incorporated | $540.26 | -2.14% | $137B | 98 |
| REGN Regeneron Pharmaceuticals, Inc. | $835.15 | -0.68% | $86.0B | 94 |
| ALNY Alnylam Pharmaceuticals, Inc. | $229.30 | -5.49% | $30.7B | 92 |
| RPRX Royalty Pharma plc | $60.58 | -1.86% | $26.9B | 75 |
| INCY Incyte Corporation | $127.80 | -0.53% | $25.9B | 99 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are FMTX's Key Strengths?
Innovative pipeline of targeted therapies.
- Strong intellectual property portfolio.
- Strategic partnership with Novo Nordisk.
- Experienced management team.
What Are FMTX's Weaknesses?
Dependence on clinical trial outcomes.
- High research and development costs.
- Regulatory approval risks.
- Competition from larger pharmaceutical companies.
What Could Drive FMTX Stock Higher?
Phase II trial results for Olutasidenib in relapsed/refractory acute myeloid leukemia.
- Phase I trial results for FT-4202 in sickle cell disease and other hemoglobinopathies.
- Development and advancement of FT-7051 for metastatic castration-resistant prostate cancer.
- Continued research and development of FT-8225 for liver-related conditions.
What Are the Key Risks for FMTX?
Negative return on equity (-30.2%) — the business is not currently generating profit on shareholder capital.
- Clinical trial failures for key drug candidates.
- Regulatory setbacks in obtaining approval for new therapies.
- Competition from existing and emerging therapies in the market.
- Pricing pressures from healthcare payers and government regulations.
What Are the Growth Opportunities for FMTX?
- Expansion of FT-4202 into New Hemoglobinopathies: FT-4202, currently in Phase 1 for sickle cell disease, holds potential for treating other hemoglobinopathies. The global market for hemoglobinopathy treatments is projected to reach $10 billion by 2028. Successful clinical trials and regulatory approval could expand FT-4202's market reach, addressing a broader patient population with limited treatment options. This expansion leverages Forma's existing research and development infrastructure, providing a competitive advantage in the rare disease market. The timeline for this expansion depends on clinical trial results and regulatory pathways.
- Advancement of Olutasidenib in Acute Myeloid Leukemia (AML): Olutasidenib, a selective inhibitor for cancers with isocitrate dehydrogenase 1 gene mutations, is in Phase II trial for relapsed/refractory AML. The AML market is expected to reach $3.8 billion by 2027. Positive Phase II results and subsequent Phase III trials could lead to regulatory approval and commercialization, capturing a significant share of the AML treatment market. Forma's targeted approach offers a potential advantage over traditional chemotherapy, providing a more effective and less toxic treatment option. The timeline for commercialization is contingent on clinical trial success and regulatory review.
- Development of FT-7051 for Metastatic Castration-Resistant Prostate Cancer (mCRPC): FT-7051 is being developed for the treatment of mCRPC, a significant unmet medical need. The global mCRPC market is projected to reach $12 billion by 2028. Successful clinical trials and regulatory approval could position FT-7051 as a valuable treatment option for patients with advanced prostate cancer. Forma's innovative approach may offer advantages over existing therapies, providing improved outcomes and quality of life for patients. The timeline for this development depends on clinical trial progress and regulatory pathways.
- Exploration of FT-8225 for Liver-Related Conditions: FT-8225, a liver-targeted fatty-acid synthase inhibitor, is designed to block de novo lipogenesis in the liver. This mechanism of action has potential applications in treating non-alcoholic steatohepatitis (NASH) and other liver diseases. The NASH market is expected to reach $20 billion by 2030. Successful preclinical and clinical development could lead to FT-8225 becoming a valuable therapy for liver-related conditions, addressing a growing global health concern. Forma's targeted approach offers a potential advantage in this competitive market.
- Leveraging Novo Nordisk's Resources for Global Expansion: As a subsidiary of Novo Nordisk, Forma Therapeutics can leverage its parent company's extensive resources and global reach to accelerate its clinical programs and commercialization efforts. Novo Nordisk's established infrastructure and expertise in drug development and marketing can significantly enhance Forma's ability to bring its therapies to market worldwide. This partnership provides Forma with a competitive advantage in terms of funding, regulatory support, and market access, enabling it to expand its global footprint and reach a broader patient population. The timeline for this expansion is dependent on regulatory approvals and strategic alignment with Novo Nordisk's global strategy.
What Opportunities Does FMTX Have?
- Expansion into new therapeutic areas.
- Development of new drug candidates.
- Partnerships with other pharmaceutical companies.
- Global expansion through Novo Nordisk's network.
What Are FMTX's Competitive Advantages?
- Proprietary drug development platform for targeted therapies.
- Strong intellectual property portfolio with patents protecting its drug candidates.
- Focus on rare diseases and cancers with high unmet medical needs.
- Strategic partnership with Novo Nordisk providing financial and operational resources.
What Does FMTX Do?
Forma Therapeutics Holdings, Inc. was founded in 2007 and is headquartered in Watertown, Massachusetts. The company is dedicated to the discovery, development, and commercialization of innovative therapeutics for rare hematologic diseases and cancers. Forma's research and development efforts are centered on addressing unmet medical needs through targeted therapies. Its core product candidates include FT-4202, currently in Phase 1 trial for sickle cell disease and other hemoglobinopathies, and FT-7051, designed for the treatment of metastatic castration-resistant prostate cancer. Additionally, Forma is developing Olutasidenib, a selective inhibitor for cancers with isocitrate dehydrogenase 1 gene mutations, which is in Phase II trial for relapsed/refractory acute myeloid leukemia and Phase I trial for glioma. FT-8225, a liver-targeted fatty-acid synthase inhibitor, is also under development to block de novo lipogenesis in the liver. As of October 14, 2022, Forma Therapeutics Holdings, Inc. operates as a subsidiary of Novo Nordisk A/S, marking a significant evolution in its corporate structure and strategic direction. This acquisition provides Forma with enhanced resources and capabilities to advance its clinical programs and expand its reach in the biopharmaceutical market. Forma's focus on rare diseases and cancers positions it within a specialized segment of the healthcare industry, where targeted therapies and personalized medicine are increasingly important.
What Products and Services Does FMTX Offer?
- Develop novel therapeutics for rare hematologic diseases.
- Create treatments for various types of cancer.
- Focus on targeted therapies for unmet medical needs.
- Conduct clinical trials to evaluate the safety and efficacy of drug candidates.
- Seek regulatory approval for new drugs from agencies like the FDA.
- Commercialize approved therapies to improve patient outcomes.
- Research and develop innovative approaches to treat diseases.
How Does FMTX Make Money?
- Develop and patent novel therapeutic compounds.
- Conduct preclinical and clinical research to validate drug efficacy and safety.
- Partner with pharmaceutical companies for commercialization and distribution.
- Generate revenue through licensing agreements and royalties.
- Focus on rare diseases and cancers with high unmet medical needs.
What Industry Does FMTX Operate In?
Forma Therapeutics Holdings, Inc. operates within the biotechnology industry, which is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. The market for rare hematologic diseases and cancers is growing, driven by advancements in personalized medicine and targeted therapies. Forma's focus on these specialized areas positions it within a niche market with significant growth potential. The competitive landscape includes both large pharmaceutical companies and smaller biotech firms developing similar therapies. The industry is subject to regulatory scrutiny and pricing pressures, which can impact the commercial success of new drugs. The global biotechnology market is projected to reach $3.44 trillion by 2030, growing at a CAGR of 12.3% from 2022.
Who Are FMTX's Key Customers?
- Patients with rare hematologic diseases.
- Patients with various types of cancer.
- Healthcare providers who prescribe and administer the company's therapies.
- Pharmaceutical companies that partner with Forma for drug development and commercialization.
- Research institutions and academic centers involved in clinical trials.
Company Profile
Forma Therapeutics Holdings, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Watertown, US. The company is led by CEO Frank D. Lee. FMTX has traded publicly since 2020.
Key Financial Metrics
Return on equity for Forma Therapeutics Holdings, Inc. stands at -30.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -30.8%, showing how much profit it generates from its asset base. A current ratio of 13.86 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -21.0%, the inverse of the P/E and a quick read on earnings relative to price.
FMTX Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Forma's recent insider buying suggests confidence from those closest to the company, often a positive signal.
- Community sentiment indicates growing optimism about Forma's pipeline, particularly its lead drug candidate.
- The market seems to be acknowledging the potential of Forma's targeted therapies, leading to increased investor interest.
- Recent developments in the hematology space, where Forma operates, are creating a favorable environment for companies with innovative treatments.
Bear Case
- Despite insider buying, overall trading volume remains relatively low, indicating limited broader market conviction.
- Community discussions reveal concerns about potential competition and market saturation in Forma's therapeutic areas.
- Market perception is vulnerable to negative news regarding clinical trial outcomes, a constant risk in the biotech sector.
- Forma's reliance on a few key assets makes it susceptible to setbacks if those programs face challenges.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
FMTX Latest News
No recent news available for FMTX.
Leadership: Frank D. Lee
CEO
Frank D. Lee is the CEO of Forma Therapeutics Holdings, Inc. He has extensive experience in the biopharmaceutical industry, with a focus on drug development and commercialization. Prior to joining Forma, he held leadership positions at various pharmaceutical companies, where he oversaw the development and launch of several successful products. His expertise spans across multiple therapeutic areas, including oncology and hematology. Lee holds a degree in Biology and an MBA from a leading business school.
Track Record: Under Frank D. Lee's leadership, Forma Therapeutics has advanced its pipeline of novel therapeutics for rare hematologic diseases and cancers. He has overseen the progress of key drug candidates through clinical trials and has successfully secured partnerships with pharmaceutical companies. A significant milestone during his tenure was the acquisition of Forma by Novo Nordisk in October 2022, which provided the company with enhanced resources and capabilities.
What Investors Ask About Forma Therapeutics Holdings, Inc. (FMTX) — Healthcare
What happened to Forma Therapeutics Holdings, Inc. (FMTX) stock?
Forma Therapeutics Holdings, Inc. (FMTX) no longer trades on public markets. It was delisted in October 2022. The figures below are historical and are not a current quote.
Can I still buy FMTX shares?
No. FMTX stopped trading on public markets in October 2022, so the shares are not available through a broker. Anything you see quoted for FMTX elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before FMTX stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to Forma Therapeutics Holdings, Inc.. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
What does Forma Therapeutics Holdings, Inc. do?
Forma Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company dedicated to discovering, developing, and commercializing novel therapeutics for rare hematologic diseases and cancers. The company's pipeline includes treatments for sickle cell disease, prostate cancer, acute myeloid leukemia, and liver-related conditions. Forma focuses on targeted therapies that address unmet medical needs, aiming to improve patient outcomes and quality of life.
What do analysts say about FMTX stock?
As of October 14, 2022, Forma Therapeutics Holdings, Inc. operates as a subsidiary of Novo Nordisk A/S, and is no longer a publicly traded company. Prior to the acquisition, analyst ratings and price targets reflected expectations for the company's pipeline and clinical trial progress. Key valuation metrics included potential revenue from successful drug candidates and the company's cash position.
What are the main risks for FMTX?
The main risks for Forma Therapeutics Holdings, Inc. include the inherent uncertainties associated with clinical trial outcomes, regulatory approvals, and competition from other biopharmaceutical companies. Clinical trial failures for key drug candidates could significantly impact the company's pipeline and future prospects. Regulatory setbacks in obtaining approval for new therapies could delay or prevent commercialization.
What are the key growth opportunities for FMTX in healthcare?
Forma Therapeutics Holdings, Inc.'s key growth opportunities in healthcare lie in the expansion of its existing pipeline and the development of new drug candidates. The successful advancement of FT-4202 into new hemoglobinopathies, the progress of Olutasidenib in acute myeloid leukemia, and the development of FT-7051 for metastatic castration-resistant prostate cancer all represent significant growth drivers.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- The company was acquired by Novo Nordisk A/S on October 14, 2022.